Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Buy” by Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been assigned an average recommendation of “Buy” from the eleven ratings firms that are covering the company, Marketbeat reports. Ten analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $58.50.

Several analysts have recently commented on the stock. Truist Financial assumed coverage on shares of Palvella Therapeutics in a report on Monday, July 21st. They issued a “buy” rating and a $56.00 price objective on the stock. Raymond James Financial set a $54.00 price objective on shares of Palvella Therapeutics and gave the company an “outperform” rating in a report on Tuesday, August 5th. HC Wainwright upped their price objective on shares of Palvella Therapeutics from $38.00 to $75.00 and gave the company a “buy” rating in a report on Friday, August 15th. Lifesci Capital assumed coverage on shares of Palvella Therapeutics in a report on Monday, August 4th. They issued an “outperform” rating and a $90.00 price objective on the stock. Finally, Chardan Capital upped their price objective on shares of Palvella Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Friday, August 15th.

Institutional Trading of Palvella Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. boosted its holdings in Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after buying an additional 32,388 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Palvella Therapeutics during the second quarter worth $104,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Palvella Therapeutics during the second quarter worth $85,000. Marshall Wace LLP boosted its holdings in Palvella Therapeutics by 61.7% during the second quarter. Marshall Wace LLP now owns 49,077 shares of the company’s stock worth $1,106,000 after buying an additional 18,732 shares in the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in Palvella Therapeutics during the second quarter worth $110,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Trading Up 1.7%

NASDAQ:PVLA opened at $51.31 on Friday. The company has a market cap of $567.49 million, a PE ratio of -4.24 and a beta of -0.01. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $52.87. The company’s 50 day moving average is $32.41 and its two-hundred day moving average is $26.34.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.08). As a group, analysts expect that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.